WitrynaAbstract BackgroundAdjuvant immunotherapy is revolutionising care for patients with resected stage III and IV melanoma. However, immunotherapy may be associated with toxicity, making treatment decisions complicated. This study aimed to identify factors physicians and nurses considered regarding adjuvant immunotherapy for … Witryna13 kwi 2024 · Treatment with low-dose ipilimumab did not enhance the effects of nivolumab as adjuvant therapy in high-risk melanoma, researchers reported in the randomized, double-blind, phase III CheckMate 915 ...
Cancer Research UK - Science blog
Witryna2 lis 2024 · Immunotherapy for advanced cutaneous melanoma has greatly improved, but the same cannot be said for acral, mucosal and uveal melanomas. Particularly in Japan, there are many treatment opportunities for these subtypes, yet we need to find new therapeutic approaches. Many issues remain to be resolved regarding … Witryna29 maj 2024 · IMMUNOTHERAPY. ICI for resected stage IV melanoma. ... 167 patients with stage IV cutaneous melanoma and no evidence of disease after surgery and/or radiotherapy were randomly assigned (1:1:1) to ... the wachtel panel cutter
Immunotherapy for Melanoma SpringerLink
WitrynaClinical research revealed that type II IFN signaling is necessary for efficacy of anti-CTLA-4 and anti-PD-1 immunotherapy . Another analysis revealed that an … Witryna1 dzień temu · Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach J … Witryna27 maj 2024 · In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment. ... in patients with previously untreated stage III or IV … the wachuma ceremony